Tag Archives: RBC Capital Markets

Rx Hall of Shame Update: Former Insys employee pleads guilty in US opioid drug probe; case against ex CEO Michael Babich, others, in pre-trial mode.

The News: A former employee of Insys Therapeutics Inc. (Chandler AZ) pleaded guilty last week to having conspired to defraud insurers into paying for an expensive fentanyl-based drug that is… Read more »

Teva reports 4Q earnings surprise; but 2017 guidance seen “through a glass darkly.”

The News: Teva Pharmaceutical Industries Ltd. (Petach Tikva ISR) reported Monday (February 13, 2017) that fourth-quarter sales surged 33% year-over-year to $6.5 billion, topping analysts’ estimates of $6.3 billion. The company… Read more »

Insys crashes back to earth as top execs arrested; what were they thinking?

The former CEO and president of Insys Therapeutics Inc. (Chandler AZ) was among six former company executives who were arrested last Thursday (December 8, 2016) on federal charges of leading… Read more »

Lilly Alzheimer’s drug, like so many others, fails; will true breakthrough happen this century?

Eli Lilly & Co. (Indianapolis RIN) said its experimental Alzheimer’s treatment failed to slow loss of cognitive ability in patients with mild symptoms, a major setback for the company and millions of… Read more »

Community Health Adopts Poison Pill; Investors Still Unconvinced

The board of directors of Community Health Systems (Franklin TN) (CHS) has adopted a “poison pill” defense to make it harder for shareholders to accumulate a controlling interest in the… Read more »

Community Health Throwing in Towel, Say Sources; Going Private an Option?

Community Health Systems Inc. (Franklin TN), the troubled hospital operator, is exploring a possible sale of its business, Bloomberg News reported, citing “people with knowledge of the matter.” The company… Read more »

FDA Approves First Muscular Dystrophy Drug Despite Thumbs Down by Scientific Panel

Federal regulators granted tentative approval to the first drug for muscular dystrophy, following an intense public campaign from patients and doctors who pushed for the largely unproven medication. The approval… Read more »

Trump’s Prospects Starting to Stir as Clinton’s Health Remains a Question

Hillary Clinton’s personal health scare is a new market risk for jittery investors already spooked by central banks poised to disappear into the woodwork in the face of lax money policies. The 68-year-old Democratic… Read more »

Good News for Mylan after Hellish Week: Another Win in Patent War Over MS Drug; Lawyers on Both Sides Rejoice.

Teva Pharmaceutical Industries Ltd. (Petach Tikva ISR) had a third patent on its top-selling multiple sclerosis drug, Copaxone, invalidated last Thursday by a U.S. agency, a further blow to its… Read more »